CRMD Relative Valuation
CRMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRMD is overvalued; if below, it's undervalued.
Historical Valuation
CorMedix Inc (CRMD) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.97. The fair price of CorMedix Inc (CRMD) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：10.42
Fair
3.80
PE
1Y
3Y
5Y
Trailing
Forward
3.26
EV/EBITDA
CorMedix Inc. (CRMD) has a current EV/EBITDA of 3.26. The 5-year average EV/EBITDA is 1.03. The thresholds are as follows: Strongly Undervalued below -13.60, Undervalued between -13.60 and -6.29, Fairly Valued between 8.35 and -6.29, Overvalued between 8.35 and 15.67, and Strongly Overvalued above 15.67. The current Forward EV/EBITDA of 3.26 falls within the Historic Trend Line -Fairly Valued range.
3.64
EV/EBIT
CorMedix Inc. (CRMD) has a current EV/EBIT of 3.64. The 5-year average EV/EBIT is -8.21. The thresholds are as follows: Strongly Undervalued below -76.93, Undervalued between -76.93 and -42.57, Fairly Valued between 26.15 and -42.57, Overvalued between 26.15 and 60.51, and Strongly Overvalued above 60.51. The current Forward EV/EBIT of 3.64 falls within the Historic Trend Line -Fairly Valued range.
1.66
PS
CorMedix Inc. (CRMD) has a current PS of 1.66. The 5-year average PS is 4105.17. The thresholds are as follows: Strongly Undervalued below -24247.56, Undervalued between -24247.56 and -10071.19, Fairly Valued between 18281.53 and -10071.19, Overvalued between 18281.53 and 32457.90, and Strongly Overvalued above 32457.90. The current Forward PS of 1.66 falls within the Historic Trend Line -Fairly Valued range.
3.12
P/OCF
CorMedix Inc. (CRMD) has a current P/OCF of 3.12. The 5-year average P/OCF is 5.92. The thresholds are as follows: Strongly Undervalued below -68.37, Undervalued between -68.37 and -31.22, Fairly Valued between 43.07 and -31.22, Overvalued between 43.07 and 80.22, and Strongly Overvalued above 80.22. The current Forward P/OCF of 3.12 falls within the Historic Trend Line -Fairly Valued range.
3.14
P/FCF
CorMedix Inc. (CRMD) has a current P/FCF of 3.14. The 5-year average P/FCF is 5.98. The thresholds are as follows: Strongly Undervalued below -68.87, Undervalued between -68.87 and -31.45, Fairly Valued between 43.41 and -31.45, Overvalued between 43.41 and 80.84, and Strongly Overvalued above 80.84. The current Forward P/FCF of 3.14 falls within the Historic Trend Line -Fairly Valued range.
CorMedix Inc (CRMD) has a current Price-to-Book (P/B) ratio of 2.16. Compared to its 3-year average P/B ratio of 5.01 , the current P/B ratio is approximately -56.89% higher. Relative to its 5-year average P/B ratio of 4.45, the current P/B ratio is about -51.46% higher. CorMedix Inc (CRMD) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -11.23%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -11.58% , the current FCF yield is about -100.00% lower.
2.23
P/B
Median3y
5.01
Median5y
4.45
9.15
FCF Yield
Median3y
-11.23
Median5y
-11.58
Competitors Valuation Multiple
The average P/S ratio for CRMD's competitors is 0.00, providing a benchmark for relative valuation. CorMedix Inc Corp (CRMD) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 810.22%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CRMD increased by 31.36% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 11.46M to 104.28M.
The secondary factor is the P/E Change, contributed -249.36%to the performance.
Overall, the performance of CRMD in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is CorMedix Inc (CRMD) currently overvalued or undervalued?
What is CorMedix Inc (CRMD) fair value?
How does CRMD's valuation metrics compare to the industry average?
What is the current P/B ratio for CorMedix Inc (CRMD) as of Dec 05 2025?
What is the current FCF Yield for CorMedix Inc (CRMD) as of Dec 05 2025?
What is the current Forward P/E ratio for CorMedix Inc (CRMD) as of Dec 05 2025?